Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Shares rebounded strongly as bioprocessing industry destocking bottomed out and order trends stabilized. Improved visibility into...
— Conestoga Capital Advisors, LLC
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Repligen Corporation
Repligen Corporation is positioned to benefit from numerous company-specific tailwinds in 2025, making it a compelling investment in the bioprocessing space. Despite...
Repligen Corporation recently announced a strategic acquisition of BioLife Solutions to expand its capabilities in the cell therapy market. The deal, valued...
More institutional theses from Conestoga Mid Cap Composite
Clearwater Analytics faced stock weakness due to lower-than-expected second-quarter revenue guidance. However, recent strategic...
Exponent's stock declined as current growth remains below its target due to hiring lags, despite beating first-quarter expectations. The manager remains...
The manager decided to exit the position in Neogen due to persistent integration issues with 3M's food safety business and frequent changes in leadership. These struggles have...